Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way

Affiliations

¹ Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford. Electronic address: mtelli@stanford.edu.
² Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, USA.

Free article

Editorial

M L Telli et al. Ann Oncol. 2019.

Free article

. 2019 Mar 1;30(3):347-348.

doi: 10.1093/annonc/mdz040.

¹ Department of Medicine, Division of Medical Oncology, Stanford University School of Medicine, Stanford. Electronic address: mtelli@stanford.edu.
² Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle, USA.

No abstract available

Comment on

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Adams S, et al. Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518. Ann Oncol. 2019. PMID: 30475947 Clinical Trial.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Adams S, et al. Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. Ann Oncol. 2019. PMID: 30475950 Clinical Trial.